BioStem Technologies Expands Product Access in Medicaid
MWN-AI** Summary
BioStem Technologies, Inc. (OTC: BSEM), a prominent MedTech firm focused on placental-derived biologics for advanced wound care, announced a significant expansion of its product access through the Florida Medicaid program. As of November 25, 2025, BioStem’s products, VENDAJE® and VENDAJE AC®, have been included in Florida's list of covered skin substitutes, joining other state Medicaid programs like California, Texas, and Michigan. This development is pivotal for BioStem’s national reimbursement strategy, allowing increased access to its wound care solutions for a broader patient demographic.
CEO and Chairman Jason Matuszewski emphasized that this addition is not just a milestone for the company, but also a crucial improvement in making high-quality, evidence-based wound care accessible to patients across the nation. The expansion taps into the large Medicaid market in Florida, significantly enhancing BioStem's reach and reinforcing its clinical and economic value. With over 70 million Americans enrolled in Medicaid, including a substantial number of older adults, this initiative addresses a critical need within the underserved chronic wound care population.
BioStem is proactively seeking regional distributors and wound care organizations to further its distribution of the VENDAJE® portfolio in Florida and other states. The company’s products, developed using proprietary BioREtain® technology, offer protective qualities for soft tissue wounds, which are vital for effective healing.
In summary, the inclusion of BioStem's products in Florida Medicaid is expected to drive long-term growth for the company while expanding the availability of essential wound care options for patients in need.
MWN-AI** Analysis
BioStem Technologies, Inc. (OTC: BSEM) has made a pivotal advancement by securing expanded reimbursement for its products, VENDAJE® and VENDAJE AC®, within Florida Medicaid. This strategic move not only enhances patient access to cutting-edge wound care solutions, but it also positions BioStem favorably within the burgeoning advanced wound care market, projected to exceed $11 billion annually in the U.S.
The inclusion of BioStem’s offerings in one of the largest Medicaid programs significantly broadens the company’s addressable market, extending its reach to new patient populations and solidifying its operational footprint alongside existing contracts with other states like California and Texas. Investors should note that Florida’s Medicaid expansion correlates with a growing demand for high-quality, evidence-based wound care solutions among the underserved chronic wound population, estimated to be around 70 million Americans enrolled in Medicaid.
From a financial perspective, this market validation enhances BioStem's potential for revenue growth, especially as the company actively seeks regional distributors to further penetrate Florida and other covered states. The focus on distribution partnership signifies a robust outreach strategy aimed at amplifying sales and brand visibility.
For investors, the implications are clear: BioStem stands at the forefront of a market with significant growth potential, driven by its proprietary products and a commitment to improving patient outcomes. With ongoing efforts to broaden state coverage, BioStem is well-positioned to become a key player in the advanced wound care space.
As the market responds to this news, stakeholders should consider watching BSEM as it could see increased trading volume and potential price movements in the near term. Moreover, continued monitoring of BioStem’s progression in securing additional reimbursement agreements will be essential in evaluating the company’s long-term growth trajectory.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
POMPANO BEACH, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in placental-derived biologics for advanced wound care, today announced expanded reimbursement with the inclusion of VENDAJE ® and VENDAJE AC ® in Florida Medicaid’s list of covered skin substitutes.
This expansion marks a significant milestone in BioStem’s national reimbursement strategy, extending access to the company’s advanced wound care products to thirteen Medicaid programs, including California (Medi-Cal), Texas, Michigan, and now Florida.
“The addition of Florida Medicaid coverage represents a major advancement in BioStem’s mission to make high-quality, evidence-based wound care available to patients nationwide,” said Jason Matuszewski, CEO and Chairman of BioStem Technologies. “Florida is one of the largest Medicaid markets in the U.S., and inclusion of VENDAJE ® products substantially increases our addressable patient base and reinforces the clinical and economic value our technology delivers. This progress builds on early traction in other states, including initial success with Medi-Cal and Texas Medicaid. Together, these developments reflect growing validation of our clinical value and the need for high-quality wound care options for this significantly underserved population. As we look ahead, we will continue to prioritize reaching more patients by securing additional state coverage and expect expanded access to be a long-term growth driver for BioStem.”
With more than 70 million Americans enrolled in Medicaid, including approximately 7 million aged 65 and older, expanded coverage significantly strengthens BioStem’s ability to address the underserved chronic wound care population, with the advanced wound care market estimated to exceed $11 Billion annually in the U.S.
Call for Distribution Partners
BioStem is actively seeking qualified regional distributors and wound care organizations interested in representing the VENDAJE ® portfolio in Florida and other covered states. Interested parties can learn more at www.biostemtechnologies.com/partners or contact the Company directly at distributors@biostemtech.com .
About VENDAJE ® and VENDAJE AC ®
VENDAJE ® and VENDAJE AC ® are placental-derived, minimally manipulated dehydrated tissue allografts that serve as a protective covering for soft tissue wounds. The product is produced using the Company’s proprietary BioREtain ® technology, which optimizes the retention of the extracellular matrix scaffolding that provides mechanical protection, as well as growth factors, cytokines and other molecular factors that are inherent to the native tissue.
About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain ® processing method. BioREtain ® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE ® , VENDAJE AC ® , VENDAJE OPTIC ® , American Amnion, and American AC. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit biostemtechnologies.com and follow us on Twitter and LinkedIn .
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE , and follow us on X and LinkedIn .
Contact BioStem Technologies, Inc.:
Website: www.biostemtechnologies.com
E-Mail: pr@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342
Investor Relations:
Philip Trip Taylor, Gilmartin Group
E-Mail: ir@biostemtech.com
FAQ**
How does BioStem Technologies Inc BSEM plan to leverage the expanded Medicaid coverage in Florida to enhance its market penetration and grow its revenue from advanced wound care products?
With the inclusion of VENDAJE® products in Florida Medicaid, what specific strategies will BioStem Technologies Inc BSEM adopt to educate healthcare providers about the clinical benefits of its placental-derived biologics?
Considering the competitive landscape of the advanced wound care market, how does BioStem Technologies Inc BSEM differentiate its products and ensure they meet the needs of the underserved chronic wound care population?
What are the long-term growth projections for BioStem Technologies Inc BSEM following the expansion of its product offerings within Medicaid programs across multiple states, and how will this impact its overall business strategy?
**MWN-AI FAQ is based on asking OpenAI questions about BioStem Technologies Inc (OTC: BSEM).
NASDAQ: BSEM
BSEM Trading
-10.85% G/L:
$5.1886 Last:
50,334 Volume:
$5.71 Open:
